2026-09-20T18:48:33Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1392502023-11-08T21:37:38Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Li, Danielle
Kim, Soomi
Sloan School of Management
2022-01-14T14:59:25Z
2022-01-14T14:59:25Z
2021-06
2021-06-03T17:55:19.076Z
https://hdl.handle.net/1721.1/139250
This paper studies how insurance coverage policies impact pharmaceutical innovation. In the United States, most patients obtain prescription drugs through insurance plans administered by Pharmacy Benefit Managers (PBMs). Beginning in 2012, PBMs began refusing to provide coverage for many newly approved drugs when cheaper alternatives were available. We show that this policy reshaped upstream pharmaceutical R&D, shifting investments away from therapeutic classes at greater risk of exclusion. This move translated into a relative decline in the development of drug candidates that appear more incremental: that is, those in drug classes with more pre-existing therapies and with less scientifically novel research.
S.M.
Massachusetts Institute of Technology
In Copyright - Educational Use Permitted
Copyright MIT
http://rightsstatements.org/page/InC-EDU/1.0/
Insurance Design and Pharmaceutical Innovation
Thesis
application/pdf
Master
Master of Science in Management Research
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="bd4b85c0-7139-4744-814e-7683c44bb4d0">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Title>Insurance Design and Pharmaceutical Innovation</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2021-06</PublicationDate>
<Authors>
<Author>
<DisplayName>Kim, Soomi</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://rightsstatements.org/page/InC-EDU/1.0/</License>
<Abstract>This paper studies how insurance coverage policies impact pharmaceutical innovation. In the United States, most patients obtain prescription drugs through insurance plans administered by Pharmacy Benefit Managers (PBMs). Beginning in 2012, PBMs began refusing to provide coverage for many newly approved drugs when cheaper alternatives were available. We show that this policy reshaped upstream pharmaceutical R&D, shifting investments away from therapeutic classes at greater risk of exclusion. This move translated into a relative decline in the development of drug candidates that appear more incremental: that is, those in drug classes with more pre-existing therapies and with less scientifically novel research.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>